Compare SD & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SD | PRTC |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.9M | 386.7M |
| IPO Year | 2007 | N/A |
| Metric | SD | PRTC |
|---|---|---|
| Price | $14.91 | $16.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 391.6K | 5.1K |
| Earning Date | 11-05-2025 | 08-28-2025 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | ★ 40.92 | N/A |
| EPS | ★ 1.79 | 0.20 |
| Revenue | ★ $155,930,000.00 | $6,391,000.00 |
| Revenue This Year | $31.95 | N/A |
| Revenue Next Year | $16.82 | N/A |
| P/E Ratio | $8.50 | ★ $7.86 |
| Revenue Growth | 29.68 | ★ 1265.60 |
| 52 Week Low | $8.81 | $13.30 |
| 52 Week High | $15.56 | $23.35 |
| Indicator | SD | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 66.30 | 49.77 |
| Support Level | $13.70 | $16.01 |
| Resistance Level | $15.56 | $18.05 |
| Average True Range (ATR) | 0.43 | 0.34 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 64.52 | 49.02 |
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.